
OnePlus launches five new products, including Buds 4 and smaller Watch 3 for the US
The Watch 3 43mm is exactly what it sounds like: a more compact version of the existing OnePlus wearable, which only launched in a single 47mm option. That was my colleague Victoria Song's 'big design gripe' with the original Watch 3, so a fix is certainly welcome. The new version is not only much smaller, but also drops the angular elements around the rotating crown and button for a simpler, circular design that's less distinctive, but which I certainly prefer.
The compact design comes at a cost to battery though. OnePlus says the new Watch 3 is 7 percent thinner and 28 percent lighter than the original, but it has just 50 percent of the battery life. That's still 60 hours on typical settings, but a far cry from the 120-hour battery life that was a key selling point first time round. That's despite using a much less bright display, with 1,000 nits of peak brightness, down from 2,200 in the 47mm model.
As before, it runs on Wear OS and is powered by Qualcomm's Snapdragon W5 Gen 1 chipset, with a second low-power chip to help with battery life. There are some new features too, with reproductive cycle tracking, and an updated version of its 'Wellness' score that claims to use the watch's barometer to measure your fatigue levels and show you a corresponding emoji as a result. The Watch 3 43mm is available from the OnePlus website from today for $299.99 — $100 less than the larger model — and will arrive on Amazon and Best Buy in August. In Europe it'll set you back €299 / £269.
The other US release is the Buds 4, a new pair of affordable earbuds. Available in green or gray, these support both Hi-Res and spatial audio, powered by dual 11mm and 6mm drivers in each bud. I'm a fan of the slightly concave touch controls, which make it easier to feel where you're meant to swipe and tap. They cost $129.99 in the US, and €119 / £119 in Europe.
The Nord 5 is the star of the other launches, though it won't come to the US. This midrange phone launches in Europe for €449 / £399, powered by the Snapdragon 8S Gen 3. There's a clear gaming focus, with a 144Hz OLED display, but also an unexpectedly capable 50-megapixel selfie camera. This one's for the kids, I guess.
It's a big phone, with a 6.83-inch display, but it's relatively slim and light, so doesn't feel too bulky from my time testing the phone so far. It also follows the Asia-only OnePlus 13S (known as the 13T in China) in dropping the company's classic Alert Slider in favor of a new button, the Plus Key. This is fully customizable, but by default triggers (you guessed it!) AI stuff. I'm reviewing the Nord 5 right now, so we'll have a full verdict on the phone soon.
It's joined by the Nord CE 5, a €349 / £299 handset that looks similar but makes compromises across the board. It's a hair smaller, with a 6.77-inch screen, and drops to a slower MediaTek Dimensity 8350 Apex chipset. The screen has a lower resolution, refresh rate, and peak brightness, and the camera specs are less impressive too, though at least it includes the same 5,200mAh battery and 80W charging speed as the Nord 5, and a similar promise of four years of OS updates. I'd pay a little more for the Nord 5 if you can afford to.
Finally, the Pad Lite is a cheaper take on the OnePlus tablet line-up. I'm disappointed to see it uses the ugly circular camera design of the older Pads (since changed on the recent Pad 3), but otherwise there's a lot to like for the price. It has an 11-inch, 2K display (though only at 90Hz), and a decently sized 9,340mah battery. It's just €229 / £199, but an extra €30 / £30 will net you more RAM, double the storage, and LTE support, which sounds like a bargain.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
This AI Stock Has Nearly Tripled in the Last Year
Symbotic (SYM) set a new 52-week high in morning trading on Aug. 5. The stock is showing strong technical momentum with a 100% 'Buy' signal via Barchart. Shares are up more than 170% over the past 52 weeks. Wall Street sentiment is bullish, with multiple 'Strong Buy' ratings and a consensus price target well above current levels. Today's Featured Stock Valued at $33.35 billion, Symbotic (SYM) is an automation technology company reimagining the supply chain with its end-to-end, artificial intelligence-powered robotic and software platform. What I'm Watching I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker 'buy' signal. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! SYM checks those boxes. Since the Trend Seeker signaled a buy on May 8, the stock has gained 136.3%. SYM Price vs. Daily Moving Averages: Barchart Technical Indicators for Symbotic Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report. These technical indicators form the Barchart Opinion on a particular stock. Symbotic shares hit a new 52-week high on Aug. 5, touching $62.61 in intraday trading. Symbotic has a Weighted Alpha of +213.61. Symbotic has a 100% 'Buy' opinion from Barchart. The stock has gained 172.36% over the past year. SYM has its Trend Seeker 'Buy' signal intact. Symbotic is trading above its 20-, 50-, and 100-day moving averages. The stock made 10 new highs and gained 30.53% in the last month. Relative Strength Index (RSI) is at 72.76%. There's a technical support level around $53.16. Don't Forget the Fundamentals $33.35 billion market capitalization. Revenue is projected to grow 20.96% this year and another 31.43% next year. Earnings are estimated to increase 132.24% next year. Analyst and Investor Sentiment on Symbotic I don't buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping a stock, it's hard to make money swimming against the tide. It looks like Wall Street analysts are bullish on SYM, and so are most major advisory sites. The Wall Street analysts tracked by Barchart have issued 7 'Strong Buy,' 1 'Moderate Buy,' 9 'Hold,' and 1 'Sell' opinion on the stock. Value Line gives the company its above-average rating with a price target of $74. CFRA's Market Scope rates the stock a 'Strong Buy.' Morningstar thinks the stock is fairly valued. 12,520 investors monitor the stock on Seeking Alpha, which rates the stock a 'Hold.' The Bottom Line on Symbotic Stock Symbotic currently has momentum and is hitting new highs. It has positive sentiment from Wall Street, plus analysts project double-digit increases in revenue and earnings. That said, I caution that SYM is volatile and even speculative in the current environment, which means investors should use strict risk management and stop-loss strategies. Today's Chart of the Day was written by Jim Van Meerten. Read previous editions of the daily newsletter here. Additional disclosure: The Barchart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance. On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
14 minutes ago
- Yahoo
MEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset
San Diego-based MEI Pharma (NASDAQ:MEIP) has acquired 929,548 Litecoin (CRYPTO: LTC) tokens, becoming the first U.S.-listed public company to adopt Litecoin as its primary treasury reserve asset. What Happened: The acquisition, valued at approximately $110.4 million as of Aug. 4, marks the launch of a $100 million institutional treasury strategy in collaboration with crypto market maker GSR and Litecoin creator Charlie Lee. The company said it purchased the LTC tokens at an average price of $107.58, positioning the crypto asset as a strategic alternative to traditional reserve holdings. The move follows a broader trend of public firms exploring digital assets as part of long-term capital diversification. 'Litecoin has long embodied sound, scalable, and decentralized money,' said Charlie Lee, who also sits on MEI's board. "By initiating this strategy, MEI is taking a clear, institutional step forward that recognizes Litecoin's role as both a reserve asset and an integral part of global financial systems." MEI's treasury model is being guided by GSR, a leading crypto investment and trading firm, which will advise on market structure, governance, and execution. Also Read: Why Litecoin? The firm cited several reasons behind its decision: 13+ years of uptime: Litecoin remains one of the most reliable blockchains in terms of network availability. Low fees and fast settlements: Ideal for treasury and operational use cases. Ecosystem adoption: Litecoin is already integrated into platforms like PayPal (NASDAQ:PYPL), BitPay, Venmo, and Robinhood (NASDAQ:HOOD), offering significant merchant and user traction. MEI Pharma's move follows in the footsteps of other publicly traded firms holding crypto in treasury, though this is the first such bet on Litecoin. Strategy holds 628,791 Bitcoin ($46.8 billion as of recent filings). Tesla holds 11,509 Bitcoin, representing 0.055% of the total Bitcoin supply. Coinbase (NASDAQ:COIN) holds 11,776 Bitcoin and CleanSpark (NASDAQ:CLSK) controls 12,608 Bitcoin, or about 0.060% of the total supply. Galaxy Digital owns 12,830 Bitcoin, equal to 0.061% of the total supply. Investment firm Metaplanet (OTC:MTPLF) holds 17,595 Bitcoin, worth 0.084% of the global supply. Trump Media & Technology Group Corp. (NASDAQ:DJT) owns 18,430 Bitcoin. Unlike these companies, MEI is the first to exclusively adopt LTC as a primary reserve asset, a notable move given Litecoin's reputation for reliability but generally lower profile in corporate circles compared to BTC or (CRYPTO: ETH). MEI indicated that further changes to its corporate identity are forthcoming, signaling a broader pivot towards fintech and possibly even Litecoin mining. Despite this, the company emphasized its continued focus on its drug candidate pipeline, including voruciclib, a CDK9 inhibitor currently in pre-clinical stages. Read Next: Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article MEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

Yahoo
14 minutes ago
- Yahoo
Advanced Micro Devices' GPU Price Increase Signals Confidence Against Competition, Zacks Says
Advanced Micro Devices (AMD) recently raised the price of its MI350 Series AI graphics processing un Sign in to access your portfolio